Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelos Becoms Azelon; Restructures To Close A Series A

This article was originally published in The Pink Sheet Daily

Executive Summary

The osteoporosis drug company has revamped its focus and brought in new investors as it pushes forward with its nasal spray for osteoporosis.

You may also be interested in...



Recapitalization Becomes A Better Alternative In A Weak Economy

Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.

Recapitalization Becomes A Better Alternative In A Weak Economy

Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.

After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone

Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel